Loading
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Latest quote
$21.21
+$0.34 · +1.63%
After-hours
$21.21
$0.00 · 0.00%
Oct 9, 5:34 PM ET
Regular session · ET · Market data may be delayed.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Day range
Current $21.21
52-week range
Current $21.21
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
100
Deep Value
Sentiment
80
Bullish
Risk
24
Moderate Risk
Momentum
48
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Day range
Current $21.21
52-week range
Current $21.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 425.13M USD | 358.71M USD | 310.46M USD | 331.34M USD | 391.87M USD |
| Cost of goods sold | 117.61M USD | 36.6M USD | 42.64M USD | 13.79M USD | — |
| Gross profit | 307.52M USD | 322.11M USD | 267.82M USD | 317.55M USD | 391.87M USD |
| Research and development | 30.6M USD | 13.65M USD | 33.92M USD | 41.43M USD | 576K USD |
| Selling, general, and administrative | 113.17M USD | 115.69M USD | 98.23M USD | 63.54M USD | 16.19M USD |
| Operating expenses | 143.77M USD | 155.25M USD | 153.94M USD | 110.55M USD | 16.76M USD |
| Interest income | 21.09M USD | 19.14M USD | 15.82M USD | 6.37M USD | 1.84M USD |
| Interest expense | 16.7M USD | 22.21M USD | 19.16M USD | 15.79M USD | 19.07M USD |
| Depreciation and amortization | 40.23M USD | 39.85M USD | 35.71M USD | 19.51M USD | 13.83M USD |
| Operating income | 163.75M USD | 166.87M USD | 113.89M USD | 207M USD | 375.1M USD |
| Net income | 271.17M USD | 23.39M USD | 179.72M USD | 213.92M USD | 265.85M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI46.35M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM41.49M0.05%77.7B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB33.43M0.02%185.3B USD0.03%$289.48+0.64%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV30.22M0.11%26.91B USD0.33%$37.95-0.39%
Dimensional - US Targeted Value ETFDFAT22.29M0.07%30.26B USD0.33%$67.27-0.43%
Vanguard Morningstar Small-Cap Value ETFVBR21.28M0.03%68.2B USD0.05%$234.43+0.22%
Invesco Pharmaceuticals ETFPJP17.43M3.22%543.56M USD0.58%$122.88+1.56%
Vanguard Extended Market ETFVXF16.94M0.02%95.4B USD0.05%$235+0.80%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBU.S. Small Cap Value Portfolio ETF Class SharesDFSVDimensional - US Targeted Value ETFDFATVanguard Morningstar Small-Cap Value ETFVBRInvesco Pharmaceuticals ETFPJPVanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
